Human PAI-1 (stable mutant, no LRP binding)


SKU: HPAI-R76E-I91L Categories: ,

Product Description

Human PAI-1 (stable mutant, no LRP binding)

A substitution of Glutamic Acid for Arginine at position 76 greatly decreases the binding of this Human PAI-1 mutant to the low density lipoprotein receptor-related protein (LRP). The putative LRP binding exosite is thought to overlap with the heparin binding site on the PAI-1 molecule. Binding to LRP or similar receptors leads to the clearance of PAI-1 complexes. An additional mutation (Isoleucine 91 to Leucine) provides increased stability for use in long term binding experiments or in vivo studies. A human PAI-1 point mutation stable form (Catalog Number HPAI-I91L) is available as an LRP binding control PAI-1.

Stefansson S. et al. (1998) J Biol Chem 273:6358-6366.

Gene ID: 5054
Swiss-Prot/UniProt ID: P05121

View sample datasheet
View sample certificate of analysis
View material safety data sheet
Ask a question about this product

Additional Information



Molecular Weight

Extinction Coefficient



Shipping Conditions




Sample Size

Sample Concentration

Sample Volume

Gene Name

Gene ID

UniProt ID

1. Sashindranath M, Sales E, Daglas M et-al. The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans. Brain. 2012;135 (Pt): 3251-64. doi:10.1093/brain/aws178Free text at pubmedPubmed citation

2. Simone TM, Higgins SP, Archambeault J, et al. A small molecule PAI-1 functional inhibitor attenuates neointimal hyperplasia and vascular smooth muscle cell survival by promoting PAI-1 cleavage. Cell Signal. 2015;27(5):923-33. Link to article